The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

22 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
13
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.EBI
Sichuan University
78
Recent Progress in Histone Demethylase Inhibitors.EBI
University of Oxford
34
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.EBI
Glaxosmithkline
36
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.EBI
Glaxosmithkline
31
Oncoepigenomics: making histone lysine methylation count.EBI
TBA
10
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.EBI
University of Oxford
39
Inhibitors of histone demethylases.EBI
University of Copenhagen
2
Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4.EBI
Shanghai Institute of Materia Medica
4
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.EBI
GlaxoSmithKline R&D
26
5-Substituted Pyridine-2,4-dicarboxylate Derivatives Have Potential for Selective Inhibition of Human Jumonji-C Domain-Containing Protein 5.EBI
University of Oxford
43
Pharmacological inhibition of KDM5A for cancer treatment.EBI
Ningbo University
34
Targeting histone demethylase KDM5B for cancer treatment.EBI
Zhengzhou University
91
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.EBI
University College London
17
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.EBI
University of Oxford
44
Recent Advances with KDM4 Inhibitors and Potential Applications.EBI
St. Jude Children'S Research Hospital
27
Enhanced Properties of a Benzimidazole Benzylpyrazole Lysine Demethylase Inhibitor: Mechanism-of-Action, Binding Site Analysis, and Activity in Cellular Models of Prostate Cancer.EBI
Max Delbruck Center
38
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.EBI
University of Oxford
9
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.EBI
Sapienza University of Rome
35
Structure-based design and discovery of potent and selective KDM5 inhibitors.EBI
Celgene
12
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitorsBDB
Merck Sharp & Dohme
2
X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement.BDB
Weizmann Institute of Science